Trials / Conditions / Progressive Metastatic Castrate Resistant Prostate Cancer
Progressive Metastatic Castrate Resistant Prostate Cancer
3 registered clinical trials studyying Progressive Metastatic Castrate Resistant Prostate Cancer — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 NCT07206056 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC. NCT04495179 | AstraZeneca | Phase 2 |
| No Longer Available | Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trame NCT03386071 | Jonsson Comprehensive Cancer Center | — |